Early and Maintained Response Levels in Psoriasis Patients Treated with Tildrakizumab

Main Article Content

Kim A Papp
Jensen Yeung
Neil Shear
Lorne Albrecht
Charles Lynde
Jingchuan Zhang
Yang Zhao
Jeff Parno
Alan M Mendelsohn
Melinda Gooderham

Keywords

Psoriasis, Tildrakizumab, Biologics, Response

Abstract

Abstract not available.

References

1. Frampton JE. Am J Clin Dermatol. 2019;20(2):295–306.

2. Reich K, Papp KA, Blauvelt A, et al. Lancet. 2017;390(10091):276–88.

3. Reich K, Warren RB, Iversen L, et al. Br J Dermatol. 2020;182(3):605–17.